| Year |
Citation |
Score |
| 2023 |
Wang L, Yi W, Ma L, Lecea E, Hazlehurst LA, Adjeroh DA, Hu G. Inflammatory Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma: Transcriptional Signature and In Vitro Modeling. Cancers. 15. PMID 37958322 DOI: 10.3390/cancers15215148 |
0.314 |
|
| 2022 |
Jones C, Dziadowicz S, Suite S, Eby A, Chen WC, Hu G, Hazlehurst LA. Emergence of Resistance to MTI-101 Selects for a MET Genotype and Phenotype in EGFR Driven PC-9 and PTEN Deleted H446 Lung Cancer Cell Lines. Cancers. 14. PMID 35804837 DOI: 10.3390/cancers14133062 |
0.375 |
|
| 2022 |
Dziadowicz SA, Wang L, Akhter H, Aesoph D, Sharma T, Adjeroh DA, Hazlehurst LA, Hu G. Bone Marrow Stroma-Induced Transcriptome and Regulome Signatures of Multiple Myeloma. Cancers. 14. PMID 35205675 DOI: 10.3390/cancers14040927 |
0.377 |
|
| 2020 |
Jain P, Badger DB, Liang Y, Gebhard AW, Santiago D, Murray P, Kaulagari SR, Gauthier TJ, Nair R, Kumar M, Guida WC, Hazlehurst LA, McLaughlin ML. Bioactivity improvement via display of the hydrophobic core of HYD1 in a cyclic β-hairpin-like scaffold, MTI-101. Peptide Science (Hoboken, N.J.). 113: e24199. PMID 35859761 DOI: 10.1002/pep2.24199 |
0.724 |
|
| 2020 |
Chen WC, Hu G, Hazlehurst LA. Contribution of the bone marrow stromal cells in mediating drug resistance in hematopoietic tumors. Current Opinion in Pharmacology. 54: 36-43. PMID 32898723 DOI: 10.1016/j.coph.2020.08.006 |
0.39 |
|
| 2020 |
Freeman S, Elzamzamy O, Geldenhuys W, Hazlehurst L. CLIC1 is an Attractive Candidate for the Initial Binding Target of the Novel Peptide MTI‐101 The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.01945 |
0.304 |
|
| 2019 |
Toth RK, Tran JD, Muldong MT, Nollet EA, Schulz VV, Jensen CC, Hazlehurst LA, Corey E, Durden D, Jamieson C, Miranti CK, Warfel NA. Hypoxia-induced PIM kinase and laminin-activated integrin α6 mediate resistance to PI3K inhibitors in bone-metastatic CRPC. American Journal of Clinical and Experimental Urology. 7: 297-312. PMID 31511835 |
0.38 |
|
| 2019 |
Chen W, Hazlehurst L. Abstract 852: Determining the roles of ERO1-alpha and ERO1-beta in progression of multiple myeloma and drug resistance Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-852 |
0.319 |
|
| 2018 |
Sweet K, Hazlehurst L, Sahakian E, Powers J, Nodzon L, Kayali F, Hyland K, Nelson A, Pinilla-Ibarz J. A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease. Leukemia Research. 74: 89-96. PMID 30340199 DOI: 10.1016/J.Leukres.2018.10.002 |
0.391 |
|
| 2018 |
von Roemeling CA, Caulfield TR, Marlow L, Bok I, Wen J, Miller JL, Hughes R, Hazlehurst L, Pinkerton AB, Radisky DC, Tun HW, Kim YSB, Lane AL, Copland JA. Accelerated bottom-up drug design platform enables the discovery of novel stearoyl-CoA desaturase 1 inhibitors for cancer therapy. Oncotarget. 9: 3-20. PMID 29416592 DOI: 10.18632/Oncotarget.21545 |
0.328 |
|
| 2017 |
Chen WC, Kanate AS, Craig M, Petros WP, Hazlehurst LA. Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab. Cancer Management and Research. 9: 307-314. PMID 28744161 DOI: 10.2147/CMAR.S117477 |
0.33 |
|
| 2017 |
Emmons MF, Anreddy N, Cuevas J, Steinberger K, Yang S, McLaughlin M, Silva A, Hazlehurst LA. MTI-101 treatment inducing activation of Stim1 and TRPC1 expression is a determinant of response in multiple myeloma. Scientific Reports. 7: 2685. PMID 28578393 DOI: 10.1038/S41598-017-02713-0 |
0.355 |
|
| 2017 |
Li X, Nelson CG, Nair RR, Hazlehurst L, Moroni T, Martinez-Acedo P, Nanna AR, Hymel D, Burke TR, Rader C. Stable and Potent Selenomab-Drug Conjugates. Cell Chemical Biology. PMID 28330604 DOI: 10.1016/J.Chembiol.2017.02.012 |
0.307 |
|
| 2016 |
Anreddy N, Hazlehurst LA. Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma. Journal of Cellular Biochemistry. PMID 27261328 DOI: 10.1002/jcb.25617 |
0.325 |
|
| 2016 |
Sweet KL, Hazlehurst L, Sahakian E, Powers JJ, Nodzon L, Kayali F, Hyland K, Nelson A, Pinilla-Ibarz J. A Phase I Study of Ruxolitinib Plus Nilotinib in Chronic Phase CML Patients with Molecular Evidence of Disease Blood. 128: 1892-1892. DOI: 10.1182/Blood.V128.22.1892.1892 |
0.338 |
|
| 2015 |
Shay G, Hazlehurst L, Lynch CC. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities. Journal of Molecular Medicine (Berlin, Germany). PMID 26423531 DOI: 10.1007/S00109-015-1345-4 |
0.427 |
|
| 2015 |
Meads MB, Fang B, Mathews L, Gemmer J, Nong L, Rosado-Lopez I, Nguyen T, Ring JE, Matsui W, MacLeod AR, Pachter JA, Hazlehurst LA, Koomen JM, Shain KH. Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma. Oncogene. PMID 26387544 DOI: 10.1038/Onc.2015.334 |
0.403 |
|
| 2015 |
Emmons M, Hazlehurst L, Escherich S, McLaughlin M, Cuevas J, Sullivan D. Abstract 4439: Ero1L is a determinant of resistance to bortezomib and collateral sensitivity to MTI-101-induced cell death in myeloma Cancer Research. 75: 4439-4439. DOI: 10.1158/1538-7445.Am2015-4439 |
0.422 |
|
| 2015 |
Yang H, Emmons MF, Cubitt C, Shain K, Coppola D, Sullivan D, Lynch CC, Hazlehurst L, Sebti SM. Abstract 2605: The geranylgeranyltransferase I inhibitor GGTI-2418 suppresses multiple myeloma malignancy in the 5TMG1 mouse model Cancer Research. 75: 2605-2605. DOI: 10.1158/1538-7445.Am2015-2605 |
0.347 |
|
| 2014 |
Khin ZP, Ribeiro ML, Jacobson T, Hazlehurst L, Perez L, Baz R, Shain K, Silva AS. A preclinical assay for chemosensitivity in multiple myeloma. Cancer Research. 74: 56-67. PMID 24310398 DOI: 10.1158/0008-5472.Can-13-2397 |
0.417 |
|
| 2014 |
Shain KH, Meads MB, Fang B, Mathews L, Gemmer J, Nong L, Rosado-Lopez I, Ring JE, MacLeod R, Hazlehurst L, Lynch C, Pachter JA, Matsui W, Koomen J, Nguyen T. Targeting PYK2 Mediates Microenvironment-Specific Myeloma Cell Death Blood. 124: 2081-2081. DOI: 10.1182/Blood.V124.21.2081.2081 |
0.468 |
|
| 2014 |
Meads MB, Fang B, Mathews L, Gemmer J, Nong L, MacCleod R, Hazlehurst L, Koomen J, Shain KH. Abstract 4892: PYK2 mediates microenvironment-specific myeloma survival Cancer Research. 74: 4892-4892. DOI: 10.1158/1538-7445.Am2014-4892 |
0.456 |
|
| 2014 |
Blumencranz LE, Nair RR, McLaughlin ML, Haura EB, Hazlehurst LA. Abstract A07: MTI-101 induces synergistic cell kill in combination with Erlotinib in EGFR-driven lung cancer models. Clinical Cancer Research. 20: A07-A07. DOI: 10.1158/1078-0432.14Aacriaslc-A07 |
0.318 |
|
| 2013 |
Turner JG, Dawson J, Emmons MF, Cubitt CL, Kauffman M, Shacham S, Hazlehurst LA, Sullivan DM. CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo. Journal of Cancer. 4: 614-25. PMID 24155773 DOI: 10.7150/Jca.7080 |
0.4 |
|
| 2013 |
Gebhard AW, Jain P, Nair RR, Emmons MF, Argilagos RF, Koomen JM, McLaughlin ML, Hazlehurst LA. MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma. Molecular Cancer Therapeutics. 12: 2446-58. PMID 24048737 DOI: 10.1158/1535-7163.Mct-13-0310 |
0.772 |
|
| 2013 |
Sweet KL, Hazlehurst LA, Pinilla-Ibarz J. The one-two punch: combination treatment in chronic myeloid leukemia. Critical Reviews in Oncology/Hematology. 88: 667-79. PMID 23969231 DOI: 10.1016/J.Critrevonc.2013.07.017 |
0.338 |
|
| 2013 |
Schonbrunn E, Betzi S, Alam R, Martin MP, Becker A, Han H, Francis R, Chakrasali R, Jakkaraj S, Kazi A, Sebti SM, Cubitt CL, Gebhard AW, Hazlehurst LA, Tash JS, et al. Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases. Journal of Medicinal Chemistry. 56: 3768-82. PMID 23600925 DOI: 10.1021/Jm301234K |
0.73 |
|
| 2013 |
Meads M, Fang B, Mathews L, Gemmer J, Nong L, Hazlehurst LA, MacLeod R, Koomen J, Shain K. PYK2 Mediates Microenvironment-Specific Myeloma Survival Blood. 122: 4443-4443. DOI: 10.1182/Blood.V122.21.4443.4443 |
0.41 |
|
| 2013 |
Zhang X, Sweet KL, Moscinski L, Hazlehurst LA, Pinilla-Ibarz J, Zhang L. Bone Marrow Beta-Catenin Expression In Chronic Myelogenous Leukemia Patients Treated With Imatinib Blood. 122: 2739-2739. DOI: 10.1182/Blood.V122.21.2739.2739 |
0.308 |
|
| 2012 |
Nair RR, Gebhard AW, Emmons MF, Hazlehurst LA. Emerging strategies for targeting cell adhesion in multiple myeloma. Advances in Pharmacology (San Diego, Calif.). 65: 143-89. PMID 22959026 DOI: 10.1016/B978-0-12-397927-8.00006-3 |
0.755 |
|
| 2012 |
Nair RR, Tolentino JH, Hazlehurst LA. Role of STAT3 in Transformation and Drug Resistance in CML. Frontiers in Oncology. 2: 30. PMID 22649784 DOI: 10.3389/fonc.2012.00030 |
0.373 |
|
| 2012 |
Nair RR, Tolentino JH, Argilagos RF, Zhang L, Pinilla-Ibarz J, Hazlehurst LA. Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML. Leukemia Research. 36: 756-63. PMID 22209738 DOI: 10.1016/J.Leukres.2011.12.002 |
0.393 |
|
| 2012 |
Nair RR, Tolentino JH, Ugrenovic M, Jain PR, McLaughlin ML, Lancet JE, Hazlehurst LA. Mti-101 Induces Necrotic Cell Death in AML Cells Through Its Binding to Cell Surface Complexes Containing CD44 and ITGA4 Blood. 120: 869-869. DOI: 10.1182/Blood.V120.21.869.869 |
0.41 |
|
| 2012 |
Gebhard AW, Nair RR, Emmons M, Jain PR, Becker A, Koomen J, Schonbrunn E, Sullivan DM, McLaughlin ML, Hazlehurst LA. Mti-101 (cyclized HYD1) Binds to CD44 and Induces Necrotic Cell Death in Multiple Myeloma Blood. 120: 4022-4022. DOI: 10.1182/Blood.V120.21.4022.4022 |
0.751 |
|
| 2012 |
Silva AS, Khin Z, Shain KH, Baz R, Hazlehurst LA, Durand A, Gatenby R. Personalizing Myeloma Chemotherapy Using Evolutionary Computational Models and Ex Vivo Assays. Blood. 120: 2960-2960. DOI: 10.1182/blood.v120.21.2960.2960 |
0.324 |
|
| 2012 |
Khin Z, Hazlehurst L, Shain K, Gillies R, Gatenby R, Silva AS. Abstract 3194: Reverse engineering the interplay between multiple myeloma and microenvironment Cancer Research. 72: 3194-3194. DOI: 10.1158/1538-7445.Am2012-3194 |
0.436 |
|
| 2011 |
Emmons MF, Gebhard AW, Nair RR, Baz R, McLaughlin ML, Cress AE, Hazlehurst LA. Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype. Molecular Cancer Therapeutics. 10: 2257-66. PMID 21980133 DOI: 10.1158/1535-7163.Mct-11-0149 |
0.787 |
|
| 2011 |
Xiang Y, Remily-Wood ER, Oliveira V, Yarde D, He L, Cheng JQ, Mathews L, Boucher K, Cubitt C, Perez L, Gauthier TJ, Eschrich SA, Shain KH, Dalton WS, Hazlehurst L, et al. Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma. Molecular & Cellular Proteomics : McP. 10: M110.005520. PMID 21846842 DOI: 10.1074/Mcp.M110.005520 |
0.452 |
|
| 2011 |
Remily-Wood ER, Liu RZ, Xiang Y, Chen Y, Thomas CE, Rajyaguru N, Kaufman LM, Ochoa JE, Hazlehurst L, Pinilla-Ibarz J, Lancet J, Zhang G, Haura E, Shibata D, Yeatman T, et al. A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. Proteomics. Clinical Applications. 5: 383-96. PMID 21656910 DOI: 10.1002/Prca.201000115 |
0.32 |
|
| 2011 |
Emmons MF, Gebhard A, Mclaughlin M, Cress A, Hazlehurst L. Abstract 1523: α4 integrin expression is a determinant for activity of the integrin antagonist HYD1 in multiple myeloma cell lines and patient specimens Cancer Research. 71: 1523-1523. DOI: 10.1158/1538-7445.Am2011-1523 |
0.769 |
|
| 2010 |
Nair RR, Tolentino J, Hazlehurst LA. The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. Biochemical Pharmacology. 80: 602-12. PMID 20382130 DOI: 10.1016/j.bcp.2010.04.003 |
0.317 |
|
| 2010 |
Emmons M, Nair R, McLaughlin M, Eschrich S, Cress A, Hazlehurst L. Abstract 1547: Acquisition of resistance to the β1 integrin antagonist HYD1 correlates with decreased α4, α6, αV and β1 integrin expression and decreased adhesion to fibronectin, VCAM-1 and vitronectin Cancer Research. 70: 1547-1547. DOI: 10.1158/1538-7445.Am10-1547 |
0.498 |
|
| 2009 |
Yarde DN, Oliveira V, Mathews L, Wang X, Villagra A, Boulware D, Shain KH, Hazlehurst LA, Alsina M, Chen DT, Beg AA, Dalton WS. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Research. 69: 9367-75. PMID 19934314 DOI: 10.1158/0008-5472.Can-09-2616 |
0.342 |
|
| 2009 |
Turner JG, Marchion DC, Dawson JL, Emmons MF, Hazlehurst LA, Washausen P, Sullivan DM. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Research. 69: 6899-905. PMID 19690141 DOI: 10.1158/0008-5472.Can-09-0484 |
0.343 |
|
| 2009 |
Hazlehurst LA, Bewry NN, Nair RR, Pinilla-Ibarz J. Signaling networks associated with BCR-ABL-dependent transformation. Cancer Control : Journal of the Moffitt Cancer Center. 16: 100-7. PMID 19337196 DOI: 10.1177/107327480901600202 |
0.688 |
|
| 2008 |
Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA. Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Molecular Cancer Therapeutics. 7: 3169-75. PMID 18852120 DOI: 10.1158/1535-7163.Mct-08-0314 |
0.724 |
|
| 2008 |
Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2519-26. PMID 18451212 DOI: 10.1158/1078-0432.CCR-07-2223 |
0.406 |
|
| 2008 |
Hazlehurst L, Dalton WS, Yarde D, Nefedova Y, Gabrilovich D. Influence of Targeted Therapy in Redefining High-Risk Myeloma. Blood. 112: sci-7-sci-7. DOI: 10.1182/Blood.V112.11.Sci-7.Sci-7 |
0.53 |
|
| 2008 |
Shain KH, Yarde D, Mead M, Hazlehurst L, Dalton WS. β1 Integrin Adhesion Enhances IL-6 Mediated STAT3 Signaling in Multiple Myeloma Cells: Implications for Microenvironment Influence on Tumor Cell Survival and Proliferation. Blood. 112: 1706-1706. DOI: 10.1182/Blood.V112.11.1706.1706 |
0.377 |
|
| 2007 |
Lwin T, Hazlehurst LA, Li Z, Dessureault S, Sotomayor E, Moscinski LC, Dalton WS, Tao J. Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells. Leukemia. 21: 1521-31. PMID 17476277 DOI: 10.1038/Sj.Leu.2404723 |
0.335 |
|
| 2007 |
Hazlehurst LA, Argilagos RF, Dalton WS. Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells. British Journal of Haematology. 136: 269-75. PMID 17233818 DOI: 10.1111/j.1365-2141.2006.06435.x |
0.351 |
|
| 2007 |
Oliveira VA, Mathews L, Yarde D, Wang X, Boulware D, Hazlehurst LA, Chen D, Beg A, Dalton WS. NF-kB as a Regulator of FA/BRCA Gene Expression in Multiple Myeloma. Blood. 110: 3508-3508. DOI: 10.1182/Blood.V110.11.3508.3508 |
0.39 |
|
| 2006 |
Turner JG, Gump JL, Zhang C, Cook JM, Marchion D, Hazlehurst L, Munster P, Schell MJ, Dalton WS, Sullivan DM. ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood. 108: 3881-9. PMID 16917002 DOI: 10.1182/Blood-2005-10-009084 |
0.433 |
|
| 2006 |
Hazlehurst LA, Argilagos RF, Emmons M, Boulware D, Beam CA, Sullivan DM, Dalton WS. Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells. Cancer Research. 66: 2338-45. PMID 16489039 DOI: 10.1158/0008-5472.CAN-05-3256 |
0.346 |
|
| 2006 |
Yarde DN, Hazlehurst LA, Oliveira VA, Chen Q, Dalton WS. Bortezomib Enhances Melphalan Response by Altering Fanconi Anemia (FA)/BRCA Pathway Expression and Function. Blood. 108: 840-840. DOI: 10.1182/blood.V108.11.840.840 |
0.306 |
|
| 2006 |
Lwin T, Hazlehurst LA, Moscinski LC, Dalton WS, Tao J. Bone Marrow Stroma (BMS) Prevents Apoptosis of Lymphoma Cells by Upregulation of BMS-Derived B-Cell Activating Factor (BAFF) and Activation of NF-kB. Blood. 108: 2378-2378. DOI: 10.1182/blood.v108.11.2378.2378 |
0.39 |
|
| 2005 |
Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood. 106: 698-705. PMID 15802532 DOI: 10.1182/blood-2004-11-4286 |
0.358 |
|
| 2004 |
Dalton WS, Hazlehurst L, Shain K, Landowski T, Alsina M. Targeting the bone marrow microenvironment in hematologic malignancies. Seminars in Hematology. 41: 1-5. PMID 15190509 DOI: 10.1053/J.Seminhematol.2004.02.001 |
0.454 |
|
| 2004 |
Engel R, Valkov NI, Gump JL, Hazlehurst L, Dalton WS, Sullivan DM. The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells. Experimental Cell Research. 295: 421-31. PMID 15093741 DOI: 10.1016/J.Yexcr.2004.01.012 |
0.445 |
|
| 2004 |
Hazlehurst LA, Alsina M, Hacker MP. Investigations on the Mechanisms of Resistance to Pixantrone in Tumor Cells. Blood. 104: 3402-3402. DOI: 10.1182/blood.v104.11.3402.3402 |
0.387 |
|
| 2004 |
Nimmanapalli R, Hazlehurst L, Enkemann S, Alsina M, Dalton WS. Bortezomib-Induced Reversal of CAM-DR Phenotype in Myeloma Is Associated with AKT and ERK1/2 Signaling. Blood. 104: 3357-3357. DOI: 10.1182/Blood.V104.11.3357.3357 |
0.483 |
|
| 2004 |
Chen Q, Van der Sluis PC, Hazlehurst L, Dalton WS. Enhanced DNA Repair Via Fanconi Anemia/BRCA Pathway Is Involved in Melphalan-Resistant Myeloma Cells. Blood. 104: 284-284. DOI: 10.1182/Blood.V104.11.284.284 |
0.449 |
|
| 2004 |
Alsina M, Nimmanapalli R, Paul MA, Elvira G, Hazlehurst L, Enkemann S, Craig B, Dalton WS. Influence of Fibronectin,(FN), Adhesion on Gene Expression Profiles, (GEP), of Isolated Patient Myeloma Cells. Blood. 104: 2345-2345. DOI: 10.1182/Blood.V104.11.2345.2345 |
0.46 |
|
| 2003 |
Hazlehurst LA, Enkemann SA, Beam CA, Argilagos RF, Painter J, Shain KH, Saporta S, Boulware D, Moscinski L, Alsina M, Dalton WS. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Research. 63: 7900-6. PMID 14633719 |
0.378 |
|
| 2003 |
Hazlehurst LA, Landowski TH, Dalton WS. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene. 22: 7396-402. PMID 14576847 DOI: 10.1038/sj.onc.1206943 |
0.344 |
|
| 2001 |
Hazlehurst LA, Dalton WS. Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Reviews. 20: 43-50. PMID 11831646 DOI: 10.1023/A:1013156407224 |
0.379 |
|
| 2001 |
Oshiro MM, Landowski TH, Catlett-Falcone R, Hazlehurst LA, Huang M, Jove R, Dalton WS. Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 4262-71. PMID 11751528 |
0.35 |
|
| 2001 |
Damiano JS, Hazlehurst LA, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia. 15: 1232-9. PMID 11480565 DOI: 10.1038/Sj.Leu.2402179 |
0.512 |
|
| 2000 |
Anderson KC, Kyle RA, Dalton WS, Landowski T, Shain K, Jove R, Hazlehurst L, Berenson J. Multiple Myeloma: New Insights and Therapeutic Approaches. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 147-165. PMID 11701540 DOI: 10.1182/Asheducation-2000.1.147 |
0.462 |
|
| 2000 |
Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene. 19: 4319-27. PMID 10980607 DOI: 10.1038/Sj.Onc.1203782 |
0.335 |
|
| 1999 |
Hazlehurst LA, Foley NE, Gleason-Guzman MC, Hacker MP, Cress AE, Greenberger LW, De Jong MC, Dalton WS. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Research. 59: 1021-8. PMID 10070958 |
0.349 |
|
| 1999 |
Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 93: 1658-67. PMID 10029595 |
0.341 |
|
| 1998 |
Hazlehurst LA, Gros P, Dalton WS. Chromosome mediated gene transfer of drug resistance to mitoxantrone. Anticancer Research. 18: 1005-10. PMID 9615755 |
0.312 |
|
| Show low-probability matches. |